Literature DB >> 7061132

Prazosin plasma concentration and blood pressure reduction.

P Larochelle, P du Souich, P Hamet, P Larocque, J Armstrong.   

Abstract

Prazosin was administered to 16 patients with essential hypertension in an initial dose of 0.5 mg, after which the blood pressure (BP), pulse, and plasma concentrations of prazosin were measured at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 24 hours. The dose of prazosin was then increased over 16 to 20 weeks, and similar sequences of measurements were obtained twice. Eleven patients completed the 20-week course. All patients did not respond in a similar way; two distinct patterns of BP and pulse response emerged, although there was no significant difference in the pharmacokinetic parameters, namely, absorption rate constant (Ka), maximum plasma concentration (Cpmax), time to reach the maximum concentration (Tmax), prazosin plasma half-life (T 1/2), elimination rate constant (kel), prazosin plasma concentration-time curve (AUC), and clearance. Patients in Group 1 had a marked reduction (52/30 mm Hg) of BP after the first dose of prazosin, no pulse increase, and needed a small dose of prazosin to maintain an adequate BP response. Patients in Group 3 had a minimal reduction in BP (14/13 mm Hg) after a first dose, a significant pulse increase, and needed a high dose of prazosin to control their BP. We conclude that this effect might be due to a different drug-receptor interaction, and the BP response and dose could be predicted from the response of the first dose of prazosin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7061132     DOI: 10.1161/01.hyp.4.1.93

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

1.  The description and prediction of antihypertensive drug response: an individualised approach.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

2.  Dose-titration study of alfuzosin, a new alpha 1-adrenoceptor blocker, in essential hypertension.

Authors:  S Leto di Priolo; P Priore; G Cocco; C Sfrisi; J L Cazor
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 4.  Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

5.  Concentration-effect relationships and individual responses to doxazosin in essential hypertension.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

6.  The influence of alpha 1-adrenergic blockade on the acute antihypertensive effect of nifedipine.

Authors:  H E Sluiter; F T Huysmans; T A Thien; R A Koene
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man.

Authors:  J Vincent; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of prazosin--1985.

Authors:  J Vincent; P A Meredith; J L Reid; H L Elliott; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 9.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

10.  Partial agonist activity of α1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3.

Authors:  Xianlong Gao; Hazem Abdelkarim; Lauren J Albee; Brian F Volkman; Vadim Gaponenko; Matthias Majetschak
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.